Cargando…
A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy
Background and objectives: EG-Mirotin (active ingredient EGT022) targets nonproliferative diabetic retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin reverses capillary damage before NPDR progresses to an irreversible stage. EG-Mirotin safety and efficacy were investigated in patients wi...
Autores principales: | Yoo, Seunghoon, You, Dae Hyuk, Lee, Jeongyoon, Hong, H. Christian, Lee, Sung Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862301/ https://www.ncbi.nlm.nih.gov/pubmed/36676801 http://dx.doi.org/10.3390/medicina59010178 |
Ejemplares similares
-
Ocular Rigidity and Outflow Facility in Nonproliferative Diabetic Retinopathy
por: Panagiotoglou, Theonitsa, et al.
Publicado: (2015) -
Serum TNF-Alpha Level Predicts Nonproliferative Diabetic Retinopathy in Children
por: Zorena, Katarzyna, et al.
Publicado: (2007) -
Intervention with vitamins in patients with nonproliferative diabetic retinopathy: a pilot study
por: Smolek, Michael K, et al.
Publicado: (2013) -
Optical Coherence Tomography Angiography Contributions in Classification of Nonproliferative Diabetic Retinopathy
por: Kasumovic, Armin, et al.
Publicado: (2020) -
Determining Risk Factors That Affect Progression in Patients with Nonproliferative Diabetic Retinopathy
por: Chen, Dalbert J., et al.
Publicado: (2021)